Inspira Technologies Validates Next-Gen Standalone HYLA™ Blood Sensor with Clinical-Grade Accuracy, Targeting $48 Billion Heart-Lung Surgery Market

Inspira Technologies (NASDAQ: IINN) validated its Next-Generation Standalone HYLA blood sensor, reporting 94.2% accuracy for continuous pCO₂ measurement concordant within a 7 mmHg threshold.

Rhea-AI Summary

Inspira Technologies (NASDAQ: IINN) validated its Next-Generation Standalone HYLA blood sensor, reporting 94.2% accuracy for continuous pCO₂ measurement concordant within a 7 mmHg threshold. The standalone configuration targets an immediate commercial pathway into the ~$48 billion heart-lung surgery market and plans a U.S. FDA submission in 2026. The strategy emphasizes disposable optical sensors and modular software for recurring revenue and broader OR/ICU integration.

Positive

• pCO2 accuracy 94.2% concordant within a 7 mmHg threshold
• Standalone HYLA enables integration with existing heart-lung and extracorporeal systems
• Recurring revenue model from disposable optical sensors and modular software

Negative

• No FDA clearance yet; company plans submission in 2026
• Validation based on bench testing, not reported clinical trial outcomes

Argus Feb 3 session

+4.92% close to close Open Argus

Details

News Market Reaction – IINN

In the Feb 3 session, IINN gained 4.92%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement emphasized clinical‑grade validation of the standalone HYLA blood sensor, with 94....

Analysis

This announcement emphasized clinical‑grade validation of the standalone HYLA blood sensor, with 94.2% pCO₂ accuracy within a 7 mmHg threshold and positioning toward a $48–50 billion heart‑lung surgery and extracorporeal market. It extends Inspira’s strategy beyond life‑support hardware into a recurring sensor and software model. Recent history shows multiple operational and transaction milestones alongside an active $75,000,000 shelf and prior offerings, so investors may track regulatory timelines, commercialization progress, and future capital raises as key developments.

Key Figures

pCO₂ accuracy: 94.2% pCO₂ threshold: 7 mmHg Target market size: $48 billion +1 more

pCO₂ accuracy

94.2%

HYLA standalone system bench testing for continuous pCO₂ measurement

pCO₂ threshold

7 mmHg

Concordance window versus gold-standard blood gas analyzers

Target market size

$48 billion

Heart-lung surgery and extracorporeal procedures addressable market

Approx. market size

$50 billion

Broader heart-lung surgery market referenced for standalone HYLA

Historical Context

5 past events · Latest: Jan 29

5 events

1. Jan 29

   ART100 clinical adoption

   24h Move

   -0.1%

   ART100 completed evaluation and entered routine workflow at top U.S. center.

2. Jan 21

   Govt PO progress

   24h Move

   -4.6%

   Governmental validation advanced on $22.5M and $27M binding purchase orders.

3. Jan 08

   Liquid biopsy vision

   24h Move

   -0.2%

   Outlined strategic vision and framework for liquid biopsy diagnostics expansion.

4. Jan 05

   Acquisition term sheet

   24h Move

   +7.8%

   Corrected release on all‑share liquid biopsy acquisition and $15M investment.

5. Jan 05

   Acquisition term sheet

   24h Move

   +7.8%

   Initial announcement of liquid biopsy acquisition and concurrent $15M investment.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pCO₂, extracorporeal membrane oxygenation (ECMO), optical sensor, ICU, +2 more

6 terms

pCO₂ medical

"94.2% accuracy for the continuous optical measurement of Partial Pressure of Carbon Dioxide (pCO₂)"

pCO₂ is the pressure of carbon dioxide gas dissolved in the blood, measured to show how well the lungs remove CO₂ and how the body is managing its acid–base balance. For investors, pCO₂ is a safety and efficacy indicator in drug trials, respiratory devices, and procedures—abnormal values can signal side effects, treatment failure, or regulatory concerns, much like an exhaust gauge revealing engine or emissions problems.

extracorporeal membrane oxygenation (ECMO) medical

"reducing complications during heart-lung machine and extracorporeal membrane oxygenation (ECMO) procedures"

Extracorporeal membrane oxygenation (ECMO) is a hospital life-support technique that temporarily takes over the work of the lungs and/or heart by pumping a patient’s blood through an external machine that adds oxygen and removes carbon dioxide, then returns it to the body—think of it as an artificial lung and pump outside the body. Investors watch ECMO because demand for the machines, supplies, specialized staffing, and regulatory approvals can affect revenues, clinical trial outcomes, hospital costs, and the commercial prospects of medical-device and healthcare companies.

optical sensor technical

"The validation data confirms that the HYLA™ optical sensor tracks real-time patient status"

An optical sensor is a device that detects and measures light or changes in light—such as brightness, color, or motion—and converts those signals into electronic data. Investors care because these sensors act like the “eyes” of many products and systems (from smartphones and medical monitors to factory robots and autonomous vehicles), so changes in performance, cost or demand can directly affect a company’s product competitiveness and revenue potential.

ICU medical

"capable of integrating into any existing operating room or ICU workflow"

An ICU, or intensive care unit, is a hospital ward equipped and staffed to monitor and treat patients with life‑threatening illnesses or injuries that require constant attention and advanced medical support, like breathing machines or continuous medication. For investors, ICU capacity and related costs matter because high demand can signal increased use of hospital services, drive revenue for medical device and healthcare providers, strain a facility’s resources and margins, and influence regulatory and reimbursement pressures—similar to how a factory’s production line affects a manufacturer’s output and costs.

FDA regulatory

"moving rapidly toward our planned U.S. Food and Drug Administration (“FDA”) regulatory submission process in 2026"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

liquid biopsy medical

"recently proposed potential acquisition of an advanced liquid biopsy business"

A liquid biopsy is a laboratory test that looks for tiny pieces of tumor or disease-related material — such as DNA, proteins, or cells — circulating in blood or other body fluids, allowing detection and monitoring without a surgical tissue sample. For investors, it matters because these tests can speed diagnosis, guide treatment choices, enable easier repeat testing, and create recurring revenue streams if adopted widely, affecting a medical company's growth and regulatory risk profile.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company’s validation confirms 94.2% accuracy for blood pCO₂ measurement, pivot to standalone configuration opens immediate commercial pathway to global installed base of heart-lung machines and extracorporeal procedures

RA'ANANA, Israel, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira Technologies” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced the successful validation in the Company’s advanced blood labs of its Next-Generation Standalone HYLA™ System. Designed to function independently of the Company’s respiratory support devices, this new configuration allows Inspira Technologies to penetrate the broader approximately $50 billion heart-lung surgery market immediately upon clearance. In advanced bench testing, the system demonstrated 94.2% accuracy for the continuous optical measurement of Partial Pressure of Carbon Dioxide (pCO₂), a performance level that aligns with clinical needs.

The validation data confirms that the HYLA™ optical sensor tracks real-time patient status with high fidelity. The observed 94.2% accuracy for pCO₂ is a critical achievement, demonstrating concordance with gold-standard blood gas analyzers within a tight 7 mmHg threshold. By providing continuous, non-invasive visibility into a patient's metabolic status, HYLA™ eliminates the 'blind spots' associated with intermittent blood draws, potentially reducing complications during heart-lung machine and extracorporeal membrane oxygenation (ECMO) procedures.

This validation marks a strategic evolution for the HYLA™ platform. By decoupling the sensor from Inspira Technologies’ life-support hardware, the Company is advancing a standalone system capable of integrating into any existing operating room or ICU workflow. This 'universal compatibility' strategy significantly expands Inspira Technologies's total addressable market  and activates a high-margin, recurring revenue model based on the sale of disposable optical sensors and modular software upgrades.

Dagi Ben-Noon, CEO stated: "This validation confirms our technology operates at a clinical grade. By offering HYLA as a standalone solution, we can enter the market faster and serve a massive global installed base of perfusion systems, independent of our ART™ system rollout. We are moving rapidly toward our planned U.S. Food and Drug Administration (“FDA”) regulatory submission process in 2026."

Inspira Technologies is advancing this standalone direction based on extensive industry engagement identifying extracorporeal procedures as an immediate commercial opportunity. The Company’s approach supports recurring revenue through modular sensor and software upgrades and aligns with Inspira Technologies’ long-term expansion into blood-based diagnostics, including its recently proposed potential acquisition of an advanced liquid biopsy business.

About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. For more information, visit: https://inspira-technologies.com.

Forward-Looking Statements
This press release contains express or implied forward-looking statements pursuant to U.S. federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses benefits and advantages of the HYLA system and its core technology, this new configuration allows Inspira Technologies to penetrate the broader heart-lung surgery market immediately upon clearance, the size of the heart-lung surgery market, that HYLA’s 'universal compatibility' strategy significantly expands the Company's total addressable market , regulatory submission process for HYLA system and the timing thereof, extensive industry engagement and an immediate commercial opportunity, , the Company’s recurring revenue model, its long-term expansion into blood-based diagnostics and potential acquisition of an advanced liquid biopsy. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC's website at www.sec.gov.

Company Contact
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What accuracy did Inspira Technologies report for the HYLA blood sensor (IINN) on Feb 3, 2026?

The HYLA sensor achieved 94.2% accuracy for continuous pCO₂ measurement within a 7 mmHg threshold. According to the company, this bench validation shows concordance with gold-standard blood gas analyzers and aligns with clinical needs.

How does the standalone HYLA system affect Inspira Technologies' (IINN) market opportunity?

The standalone HYLA opens immediate access to an approximately $48 billion heart-lung surgery market by integrating with existing perfusion systems. According to the company, this decoupling expands total addressable market and commercial channels.

When does Inspira Technologies (IINN) plan to seek FDA clearance for the standalone HYLA?

The company plans a U.S. FDA regulatory submission in 2026. According to the company, regulatory filing is the next step after bench validation to pursue clinical clearance and commercialization.

What revenue model does Inspira Technologies (IINN) expect from the standalone HYLA sensor?

Inspira plans a high-margin recurring revenue model from the sale of disposable optical sensors and modular software upgrades. According to the company, consumables and software will drive ongoing revenue beyond initial device sales.

Does the Feb 3, 2026 validation for HYLA represent clinical trial results for Inspira (IINN)?

No; the validation reported is from advanced bench testing showing laboratory concordance for pCO₂ measurement. According to the company, further regulatory and clinical steps are planned to confirm clinical performance.